When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Sofosbuvir/velpatasvir - Wikipedia

   en.wikipedia.org/wiki/Sofosbuvir/velpatasvir

   Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [ 2 ] [ 5 ] [ 6 ] [ 7 ] It combines sofosbuvir and velpatasvir .

3. Viloxazine - Wikipedia

   en.wikipedia.org/wiki/Viloxazine

   Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.

4. List of antidepressants - Wikipedia

   en.wikipedia.org/wiki/List_of_antidepressants

   This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.

5. List of investigational attention deficit hyperactivity ...

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...

6. FDA approves opioid-free pain medication with 'no sign of ...

   www.aol.com/fda-approves-opioid-free-pain...

   A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...

7. Liquidia's inhaled drug fails to get traditional approval in ...

   www.aol.com/news/us-fda-grants-tentative...

   (Reuters) -The U.S. Food and Drug Administration on Monday delayed traditional approval for Liquidia Corp's inhaled drug for types of lung disorders, and allowed only tentative clearances, sending ...